Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Demographic and clinical characteristics of study participants.

From: Safety, efficacy, and immunogenicity of an inactivated influenza vaccine in healthy adults: a randomized, placebo-controlled trial over two influenza seasons

  Vaccine
N = 3783
Placebo
N = 3828
Mean age, years (SD) 32.7 (9.19) 32.7 (9.14)
1. Male, n (%) 1465 (39) 1520 (40)
Age stratum, n (%)   
   Age 18 - 34 2153 (57) 2181 (57)
   Age 35 - 49 1630 (43) 1647 (43)
Race, n (%)   
   Caucasian 3166 (84) 3237 (85)
   Black or African American 384 (10) 362 (9)
   Asian 61 (2) 75 (2)
   Native Hawaiian or Pacific Islander 10 (<1) 15 (<1)
   Native American/Alaskan Native 18 (<1) 9 (<1)
   Other 144 (4) 129 (3)
Received Prior Vaccination (≤ 2 years), n (%) 727 (19) 727 (19)